Status:
WITHDRAWN
STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Hepatitis C
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigators will conduct a randomized controlled trial comparing two strategies to promote HCV screening, follow-up testing, and treatment among Parkland patients who are 18 years or older who h...
Eligibility Criteria
Inclusion
- ages 18 or older
- elevated liver functioning tests (AST or ALT \>35 that are separated by at least one month)
- ≥ 1 outpatient visit during 12 months prior to randomization at Parkland
- no prior HCV screening (prior HCV antibody, viral load, or genotype).
- any active medical coverage
- speaks Spanish or English
Exclusion
- a life expectancy less than one year including any history of metastatic cancer, and those who received a palliative care or hospice referral in the past year
- history of HCC.
- non-English or Spanish speakers
- no address or phone number on file
Key Trial Info
Start Date :
August 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04395118
Start Date
August 15 2020
End Date
January 1 2022
Last Update
July 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Parkland Hospital
Dallas, Texas, United States, 75235